Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
This study has been completed.
NEMA Research, Inc.
First Posted: August 6, 2010
Last Update Posted: May 1, 2012
Information provided by (Responsible Party):
Joseph Pergolizzi, MD, NEMA Research, Inc.
Using a retrospective analysis of a large commercial claims database and a Medicare database, the investigators evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s).
|Chronic Low Back Pain|
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Joseph Pergolizzi, MD, NEMA Research, Inc.:
Contacts and Locations
No Contacts or Locations Provided